Sagira Abdrakhmanova

Sagira Abdrakhmanova

Auto-generated profile, based on publicly available information

Sagira Abdrakhmanova

JSC «Astana Medical University», Astana, Republic of Kazakhstan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Qatar Medical Journal
Verified
Journal Article
Open access
IFIman Fatima
Iman Fatima
MSMuneeb Ali Saif
Muneeb Ali Saif
AMAssylzhan Messova
Assylzhan Messova
SASagira T. Abdrahmanova
Sagira T. Abdrahmanova
NMNadiar Maratovich Mussin
Nadiar Maratovich Mussin
Amin TamadonAmin Tamadon
Amin Tamadon
Introduction: Coronavirus disease 2019 (COVID-19) is increasingly recognized as a multisystem disorder with potential endocrine sequelae. Emerging reports suggest that adrenal insufficiency (AI) may occur in patients with COVID-19 without preexisting adrenal disease, but the clinical spectrum and strength of evidence remain unclear. To systematically review the literature on new-onset AI associated with COVID-19 in patients without prior adrenal disorders, focusing on clinical presentation, diagnostic approaches, and underlying mechanisms. Methods: A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to December 28, 2025. Eligible studies included observational studies, case reports, and case series reporting AI in COVID-19 patients without known adrenal disease. Risk of bias was assessed using the Newcastle–Ottawa Scale and Joanna Briggs Institute tools. Given the heterogeneity, a qualitative synthesis was conducted. Results: Nine primary studies (two observational studies and seven case reports) were included. Four narrative reviews were used solely for contextual discussion. Cases involved adults and children and occurred during acute infection or the post-COVID period. Most reports described biochemically confirmed central AI, while fewer reported primary AI due to adrenal infarction, hemorrhage, or autoimmune adrenalitis. Some presentations based mainly on steroid responsiveness were interpreted as probable critical illness–related corticosteroid insufficiency. Diagnostic thresholds and the use of ACTH stimulation testing varied. Most patients improved with glucocorticoid replacement. Conclusion: New-onset AI has been reported in temporal association with COVID-19 and may represent an infrequently reported but clinically significant endocrine manifestation. Prospective studies with standardized hormonal assessment are needed to clarify incidence, mechanisms, and screening strategies. Registration: The review was registered with PROSPERO under registration number CRD420251275141.

10 September 2024 in Russian Journal of Allergy
Verified
Journal Article
Closed access
PDF file
NGNatalia Geppe
Natalia Geppe
AZAndrey Zaplatnikov
Andrey Zaplatnikov
EKElena Gennadievna Kondyurina
Elena Gennadievna Kondyurina
BBBoris Blokhin
Boris Blokhin
VRVera Revyakina
Vera Revyakina
NKNatalia Kolosova
Natalia Kolosova
The safety of drug therapy is of particular importance for immunocompromised patients. This aspect acquires high importance in the context of choosing tactics for the prevention and treatment of acute respiratory viral infections. The review presents data on the features of the antiviral immune response and common cold/influenza in patients with a burdened allergic history and a brief overview of the results of clinical studies on the effectiveness and safety of innovative biological antiviral drugs based on antibodies to biological targets – Ergoferon, Anaferon for children and Anaferon. The drugs have a targeted effect on the immune system in accordance with their pharmacological targets, have a significant evidence base, including a meta-analysis of clinical trials for each drug according to the indication "acute respiratory viral infections/influenza", as well as individual studies, including double-blind placebo-controlled randomized, with this pathology in immunocompromised patients. The article also includes the results of a generalized safety analysis of the use of the above drugs for the prevention and treatment of acute respiratory viral infections/influenza in patients with concomitant allergic and autoimmune pathology. The results of the conducted studies, meta-analyses and generalized statistical analysis of data on the use of the drugs Anaferon for children, Anaferon, Ergoferon for the prevention and treatment of acute respiratory viral infections/ influenza indicate proven efficacy and a favorable safety profile and allow us to recommend drugs for wide use with preventive and therapeutic purposes in accordance with indications, including patients with allergic and autoimmune pathology.

31 October 2023 in Наука и здравоохранение
Verified
Journal Article
Open access
KPKarabayeva P.K.
Karabayeva P.K.
ASAbdrakhmanova S.T.
Abdrakhmanova S.T.
ARAishauova R.R.
Aishauova R.R.
TATayr A.A.
Tayr A.A.
Relevance. The global prevalence of childhood obesity has reached alarming levels, with numerous health consequences affecting multiple organ systems. One area of increasing interest is the impact of obesity on diaphragmatic function in children. The diaphragm, as the primary muscle of respiration, plays a crucial role in maintaining effective ventilation and gas exchange. Several studies have examined the effects of obesity on diaphragmatic function in children. Evidence suggests that obesity may lead to alterations in diaphragmatic morphology and biomechanics, potentially reducing its effectiveness in facilitating respiration. Furthermore, researchers have identified potential mechanisms linking obesity and impaired diaphragmatic function, including increased abdominal pressure, decreased lung volumes, and altered neuromuscular function. Understanding the impact of obesity on diaphragmatic function in children is crucial, as it can contribute to various obesity-related respiratory complications. Diaphragmatic dysfunction may play a role in the development of obesity hypoventilation syndrome (OHS) and may exacerbate obstructive sleep apnea. These conditions can negatively affect a child's health, academic performance, and overall quality of life Aim. This literature review aims to summarize and critically assess the current body of knowledge on the condition of the diaphragm in obese children and Effects of Obesity on Diaphragm Function and Structure Search strategy. In order to compile the literature review, a thorough source search was conducted in a number of databases, including UpToDate, BMJ, PubMed, Scopus, Wiley, Medline, The Cochrane Library, Springer Link, and Web of Science. The study covered a long time period - 18 years: from 2004 to 2022. Due to the lack of knowledge of this topic, 68 articles were selected as a result of this search, which were available in full and underwent a critical evaluation process. Criteria for inclusion in the review included children's age, that is, the study of the state of the diaphragm in the pediatric population. At the same time, studies regarding the condition of the diaphragm in adults were excluded from the analysis. This approach made it possible to focus on specific aspects of the state of the diaphragm in the context of childhood. Results and conclusions.The condition of the diaphragm in obese children has emerged as a significant area of concern in recent years, with far-reaching implications for respiratory health, exercise tolerance, and overall quality of life. The complex interplay between obesity and diaphragmatic function is not yet fully understood, but existing research indicates that obesity can lead to alterations in diaphragmatic morphology, biomechanics, and neuromuscular function. These changes can contribute to a variety of obesity-related respiratory complications, such as obesity hypoventilation syndrome and obstructive sleep apnea, which can have detrimental effects on a child's well-being, cognitive performance, and social functioning. Aктуальность: Глобальная распространенность ожирения среди детей достигла тревожных уровней, что приводит к многочисленным последствиям для здоровья, затрагивающим различные органные системы. Одна из областей, вызывающих все больший интерес, — это влияние ожирения на функцию диафрагмы у детей. Диафрагма, как основной мышцы дыхания, играет важную роль в поддержании эффективной вентиляции и газообмена. Было проведено немало исследований на влияние ожирения на функцию диафрагмы у детей. Существуют данные о том, что ожирение может привести к изменениям в морфологии и биомеханике диафрагмы, возможно, снижая ее эффективность в обеспечении дыхания. Кроме того, исследователи определили возможные механизмы, связывающие ожирение и нарушение функции диафрагмы, включая увеличение брюшного давления, уменьшение объема легких и изменение нейромышечной функции. Понимание влияния ожирения на функцию диафрагмы у детей имеет решающее значение, так как это может способствовать развитию различных осложнений, связанных с ожирением. Дисфункция диафрагмы может играть роль в развитии синдрома гипоксемии, обусловленного ожирением, и может обострять обструктивный синдром апноэ сна. Эти состояния могут негативно влиять на здоровье ребенка, его успеваемость и общее качество жизни. Цель: данное обзорное исследование направлено на обобщение и критическую оценку существующих знаний о состоянии диафрагмы у детей с ожирением и влиянии ожирения на функцию и структуру диафрагмы. Стратегия поиска: для составления обзора литературы был проведен тщательный поиск источников в ряде баз данных,...

28 August 2025 in Наука и здравоохранение
Verified
Journal Article
Open access
AMAssylzhan Messova
Assylzhan Messova
ATAliya Tuleubayeva
Aliya Tuleubayeva
SAS.T. Abdrakhmanova
S.T. Abdrakhmanova
SAS.M. Altybayeva
S.M. Altybayeva
AKA.K. Kadirova
A.K. Kadirova
BAB.A. Ashirov
B.A. Ashirov
Gianotti-Crosti syndrome is a benign skin disorder, predominantly occurring in children, characterized by a symmetrical papular or papulovesicular rash localized on the face, extremities, and buttocks caused by a viral infection or hypersensitivity. We report a case of 18-month-old male child presenting with GCS with typical manifestations of this syndrome. The report offers a detailed chronology of the disease course, including the onset, evolution, and resolution of symptoms. We describe in detail the course of the disease, diagnostic signs and approach to patient management, emphasizing the importance of differential diagnosis in pediatric practice and highlighting the self-limiting nature of the syndrome. Синдром Джанотти-Крости — доброкачественное заболевание кожи, встречающееся преимущественно у детей, характеризующееся симметричной папулезной или папуловезикулярной сыпью, локализующейся на лице, конечностях и ягодицах, вызванной вирусной инфекцией или гиперчувствительностью. В статье описан случай 18-месячного мальчика с Синдромом Джанотти – Крости и типичными проявлениями этого синдрома. В работе представлена подробная хронология течения заболевания, включая начало, развитие и разрешение симптомов. Мы подробно описываем течение заболевания, диагностические признаки и подход к ведению пациента, подчеркивая важность дифференциальной диагностики в педиатрической практике и подчеркивая самоограничивающийся характер синдрома Джанотти–Крости синдромы - негізінен балаларда кездесетін, симметриялы папулалық немесе папуловезикулярлы бөртпелермен сипатталатын терінің қатерсіз зақымдануы. Бөртпелер әдетте аяқ-қолдарда, бетте және жамбас аймағында орналасады. Синдромның дамуында вирустық инфекциялар немесе жоғары сезімталдық реакциялары басты этиологиялық факторлар ретінде қарастырылады. Мақалада Джанотти-Крости синдромы бар 18 айлық баланың жағдайы және осы синдромның типтік көріністері сипатталған. Жұмыста аурудың басталуын, дамуын және симптомдардың шешілуін қоса алғанда, аурудың ағымының егжей-тегжейлі хронологиясы берілген. Аурудың клиникалық ағымы, диагностикалық ерекшеліктері және емдеу мен бақылау тәсілдері егжей-тегжейлі баяндалып, педиатриялық тәжірибеде дифференциалды диагностиканың маңыздылығы мен синдромның өздігінен шектелетін табиғаты атап өтіледі.

31 December 2022 in Vestnik
Verified
Journal Article
Closed access
ИДИ.с. Джаксыбаева
И.с. Джаксыбаева
РБР.з. Боранбаева
Р.з. Боранбаева
САС.т. Абдрахманова
С.т. Абдрахманова
РМР.с. Майтбасова
Р.с. Майтбасова
ПИП.к. Ишуова
П.к. Ишуова
НЖН.т. Жанузакова
Н.т. Жанузакова
Мультисистемный воспалительный синдром (МВС), ассоциированный с COVID-19, представляет собой тяжелое гипервоспалительное состояние у детей и подростков, связанное с предшествующей инфекцией SARS-CoV-2, характеризующееся лихорадкой, воспалением и мультисистемным поражением. Было проведено ретроспективное исследование у детей с МВС, ассоциированным с SARS-CoV-2, получавших стационарное лечение в многопрофильных детских медицинских организациях 17 регионов Казахстана c 1 августа 2020г. по 15 июня 2022г. Всего в исследование вошло 96 пациентов. У большинства пациентов наблюдались изменения в общем анализе крови, повышение маркеров воспаления. Половина детей нуждались в лечении отделение реанимации и интенсивной терапии (ОРИТ). Целью данного исследования является описание клинических проявлений и наиболее частых изменений в лабораторных показателях у детей с МВС, ассоциированным с SARS-CoV-2 в РК. COVID-19-мен ассоциирленген көп жүйелі қабыну синдромы (КҚС) – балалар мен жасөспірімдердегі SARS-CoV-2 инфекциясымен байланысты, қызбамен, қабынумен және көпжүйелі зақымданумен сипатталатын ауыр гиперқабыну жағдайы. 2020 жылдың 1- тамызынан бастап 2022 жылдың 15-маусымына дейін Қазақстанның 17 облысында көп бейінді балалар медициналық ұйымдарында стационарлық ем қабылдаған SARS-CoV-2-мен байланысты КҚС бар балаларға ретроспективті зерттеу жүргізілді. Зерттеуге барлығы 96 науқас қатысты. Пациенттердің көпшілігінде жалпы қан анализінде өзгерістер, қабыну маркерлерінің жоғарылауы байқалды. Балалардың жартысы жансақтау бөлімінде емделуді қажет етті. Multisystem inflammatory syndrome (MIS-С) associated with COVID-19 is a severe hyperinflammatory condition in children and adolescents associated with a previous SARS-CoV-2 infection, characterized by fever, inflammation and multisystem lesion. A retrospective study was conducted in children with MIS associated with SARS-CoV-2 who received inpatient treatment in multidisciplinary children's medical organizations in 17 regions of Kazakhstan from August 1, 2020 to June 15, 2022. A total of 96 patients were included in the study. The majority of patients had changes in the general blood test, increased markers of inflammation. Half of the children needed treatment in the intensive care unit (ICU). The purpose of this study is to describe the clinical manifestations and the most frequent changes in laboratory data in children with MVS associated with SARS-CoV-2 in the Republic of Kazakhstan.

28 January 2026 in Наука и здравоохранение
Verified
Journal Article
Closed access
ABA.I. Baygalkanova
A.I. Baygalkanova
SAS.T. Abdrakhmanova
S.T. Abdrakhmanova
AMAssylzhan Messova
Assylzhan Messova
GBG.K. Besbayeva
G.K. Besbayeva
ATAliya Tuleubayeva
Aliya Tuleubayeva
Introduction. The investigation of cardiorenal syndrome holds significant clinical relevance, as both cardiovascular and renal diseases rank among the leading causes of mortality. Current research efforts are focused on identifying reliable biomarkers for the early detection of acute kidney injury (AKI), which may serve as a valuable predictor for improving prognosis and therapeutic strategies in patients with chronic heart failure. The study aims to identify biomarkers associated with an increased risk of type 2 cardiorenal syndrome in children. Materials and methods. We performed a retrospective analysis with a case-control design. From the medical records of the Scientific National Cardiac Surgery Center (NNCC), we identified all pediatric patients with CHF due to DCM who had an initial hospitalization in 2022 and a subsequent re-hospitalization in 2023. Based on their diagnosis at re-hospitalization, patients were classified into two groups: the case group (those with confirmed Type 2 CRS, n=18) and the control group (those with CHF but without CRS, n=21). We then extracted and compared laboratory data from both the 2022 (baseline) and 2023 (follow-up) hospitalizations for all participants. Results. Reduced serum iron levels were observed at baseline and during follow-up in both the control and case groups (9 and 5.9 µmol/L, respectively). Elevated total bilirubin levels were also detected in both groups (0.41 µmol/L in controls and 0.55 µmol/L in cases). Notably, galectin-3 concentrations were elevated in the case group, showing a 13% increase compared to the control group. Markers of renal dysfunction, including the albumin-to-creatinine ratio (ACR) and the blood urea nitrogen-to-creatinine (BUN/Cr) ratio, were comparable between the two groups (ACR: 31 and 32 mg/g; BUN/Cr: 30 and 32, respectively). Statistically significant correlations were identified between kidney function (as measured by ACR) and levels of serum iron (p=0.05), hemoglobin (p=0.02), and galectin-3 (p=0.02). Galectin-3 was a significant predictor of renal dysfunction, with an 81% increase in the likelihood of renal dysfunction (OR = 1.81, 95% CI). Similarly, the BUN/Cr ratio was associated with a 70% increase in the likelihood of renal impairment (OR = 1.70, 95% CI). Conclusion. The findings indicate that, despite similar baseline values of key renal markers across groups, galectin-3 levels were significantly elevated in cases and were strongly associated with renal dysfunction. Reduced serum iron and elevated bilirubin levels were observed in both groups, suggesting potential systemic involvement. However, the small sample size limits the statistical power and generalizability of these findings, warranting validation in larger, prospective cohorts. Введение. Исследование кардиоренального синдрома имеет важное клиническое значение, поскольку как сердечно-сосудистые, так и почечные заболевания входят в число основных причин смертности. Текущие исследовательские усилия сосредоточены на выявлении надежных биомаркеров для раннего выявления острого повреждения почек (ОПП), которые могут служить ценным предиктором для улучшения прогноза и терапевтических стратегий у пациентов с хронической сердечной недостаточностью. Целью исследования является выявление биомаркеров, связанных с повышенным риском кардиоренального синдрома 2 типа. Материалы и методы. Было проведено ретроспективное исследование типа «случай-контроль» с участием пациентов с подтвержденным диагнозом кардиоренального синдрома (КРС) 2-го типа (n=18) во время первичной госпитализации в 2022 г. и последующей повторной госпитализации в 2023 г., которые составили группу случая. Контрольная группа включала пациентов с хронической сердечной недостаточностью (ХСН), но без клинических или лабораторных признаков КРС 2-го типа (n=21). Результаты. Снижение уровня сывороточного железа наблюдалось на исходном уровне и во время последующего наблюдения как в группе контроля, так и в группе случая (9 и 5,9) мкмоль/л соответственно). Повышенные уровни общего билирубина также были обнаружены в обеих группах (0,41 мкмоль/л в контрольной группе и 0,55 мкмоль/л в случаях). Примечательно, что концентрации галектина-3 были повышены в группе случая, показывая 13%-ное увеличение по сравнению с контрольной группой. Маркеры почечной дисфункции, включая соотношение альбумина к креатинину (ACR) и соотношение азота мочевины крови к креатинину (BUN/Cr), продемонстрировали сопоставимые значения в обеих группах (ACR: 31 и 32 мг/г; BUN/Cr: 30 и 32 соответственно)....